1
|
Aydın Kaynar L, Özkurt ZN. The Effect of Granulocyte Colony-Stimulating Factor (G-CSF) on Early Complications and Graft-Versus-Host Disease (GVHD) in Allogeneic Stem Cell Transplantation (ASCT) Recipients. Cureus 2023; 15:e46105. [PMID: 37779681 PMCID: PMC10534265 DOI: 10.7759/cureus.46105] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 09/28/2023] [Indexed: 10/03/2023] Open
Abstract
Objectives Granulocyte colony-stimulating factor (G-CSF) is commonly used to accelerate neutrophil recovery after allogeneic stem cell transplantation (ASCT) in most transplant centers. There was no consensus on the optimal use of G-CSF after ASCT. Although we use G-CSF to minimize morbidity and mortality, G-CSF can increase the risk of graft-versus-host disease (GVHD). In our study, we want to show the effect of prophylactic G-CSF on infection frequency, neutrophil and platelet engraftment, the duration of neutropenia, the development of GVHD, hospitalization time, and transplant-related mortality (TRM) after ASCT. Materials and methods One hundred (71 males and 29 females) patients who did not receive G-CSF and 100 (58 males and 42 females) patients who received prophylactic G-CSF were included in the study. Results Age, diagnosis, the time between diagnosis and transplantation, preparation regimen, donor type, and the number of infused cluster of differentiation (CD) 34+ cells were not different in both groups (p>0.05). The frequency of female patients was higher in the group receiving G-CSF. Febrile neutropenia was more frequent in patients who did not receive G-CSF. Neutrophil engraftment and platelet engraftment were detected longer in patients not receiving G-CSF. The frequency of veno-occlusive disease (VOD) and hyperacute, chronic, and acute GVHD was not different in both groups (p>0.05). One hundred-day TRM and five-year overall survival (OS) were similar in the two groups (p>0.05). Conclusions Our study supports that G-CSF usage does not cause an increase in the frequency of GVHD and has a positive effect on the process by accelerating myeloid engraftment. In light of the data in our study, we can say that the use of G-CSF should be investigated in a randomized controlled clinical trial.
Collapse
|
2
|
Lasagna A, Piralla A, Secondino S, Sacchi P, Baldanti F, Bruno R, Pedrazzoli P. Case report: Successful outcome of COVID-19 in the context of autologous hematopoietic stem cell transplantation: The impact of the anti-SARS-CoV-2 vaccine and early remdesivir. Front Med (Lausanne) 2022; 9:944855. [PMID: 35935759 PMCID: PMC9353116 DOI: 10.3389/fmed.2022.944855] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/15/2022] [Accepted: 06/28/2022] [Indexed: 11/13/2022] Open
Abstract
Coronavirus disease (COVID-19) in patients undergoing hematopoietic stem cell transplantation (HSCT) is a major issue. None of the published papers have reported data on the outcome of HSCT patients with COVID-19 according to the vaccination status and the short course of remdesivir (RDV). Therefore, we present the case of a 22-year-old man with relapsed testicular non-seminomatous germ-cell tumor who was diagnosed with COVID-19 during his first auto-HSCT. Our case report is the first one describing the efficacy of early RDV (and its anti-inflammatory effects that might counterbalance the negative effect of the recombinant human granulocyte-colony stimulating factors -rhG-CSF-) in the context of severe neutropenia following HSCT with the concomitant onset of COVID-19.
Collapse
Affiliation(s)
- Angioletta Lasagna
- Medical Oncology Unit, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy
- *Correspondence: Angioletta Lasagna
| | - Antonio Piralla
- Microbiology and Virology Department, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy
| | - Simona Secondino
- Medical Oncology Unit, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy
| | - Paolo Sacchi
- Division of Infectious Diseases I, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy
| | - Fausto Baldanti
- Microbiology and Virology Department, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy
- Department of Clinical, Surgical, Diagnostic and Pediatric Sciences, University of Pavia, Pavia, Italy
| | - Raffaele Bruno
- Division of Infectious Diseases I, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy
- Department of Clinical, Surgical, Diagnostic and Pediatric Sciences, University of Pavia, Pavia, Italy
| | - Paolo Pedrazzoli
- Medical Oncology Unit, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy
- Department of Internal Medicine and Medical Therapy, University of Pavia, Pavia, Italy
| |
Collapse
|
3
|
Pallett SJC, Wake R, Youngs J, Pope C, Tan NK, Taylor J, Hawkins L, Witney AA, Laing KG, Monahan IM, Akay M, Cox A, Groppelli E, Kelleher P, Miller P, Bicanic T. Adjunctive viral cell culture supports treatment decision-making in patients with secondary humoral immunodeficiency and persistent SARS-CoV-2 infection. Br J Haematol 2021; 196:1170-1174. [PMID: 34766331 PMCID: PMC8652771 DOI: 10.1111/bjh.17957] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/10/2021] [Accepted: 10/30/2021] [Indexed: 12/26/2022]
Affiliation(s)
- Scott J C Pallett
- Infection Care Group, St George's University Hospitals NHS Foundation Trust, London, UK.,Centre of Defence Pathology, Royal Centre for Defence Medicine, Edgbaston, Birmingham, UK
| | - Rachel Wake
- Infection Care Group, St George's University Hospitals NHS Foundation Trust, London, UK.,Institute for Infection and Immunity, St George's University of London, Cranmer Terrace, London, UK
| | - Jonathan Youngs
- Infection Care Group, St George's University Hospitals NHS Foundation Trust, London, UK
| | - Cassie Pope
- Infection Care Group, St George's University Hospitals NHS Foundation Trust, London, UK.,Institute for Infection and Immunity, St George's University of London, Cranmer Terrace, London, UK
| | - Ngee Keong Tan
- South West London Pathology, Jenner Wing, St. George's Hospital, London, UK
| | - Joshua Taylor
- South West London Pathology, Jenner Wing, St. George's Hospital, London, UK
| | - Lois Hawkins
- Infection Care Group, St George's University Hospitals NHS Foundation Trust, London, UK
| | - Adam A Witney
- Institute for Infection and Immunity, St George's University of London, Cranmer Terrace, London, UK
| | - Kenneth G Laing
- Institute for Infection and Immunity, St George's University of London, Cranmer Terrace, London, UK
| | - Irene M Monahan
- Institute for Infection and Immunity, St George's University of London, Cranmer Terrace, London, UK
| | - Melek Akay
- Department of Haematology, St George's University Hospitals NHS Foundation Trust, London, UK
| | - Alison Cox
- Centre for Immunology and Vaccinology, Department of Medicine, Imperial College London, London, UK
| | - Elisabetta Groppelli
- Institute for Infection and Immunity, St George's University of London, Cranmer Terrace, London, UK
| | - Peter Kelleher
- Centre for Immunology and Vaccinology, Department of Medicine, Imperial College London, London, UK
| | - Paul Miller
- Department of Haematology, St George's University Hospitals NHS Foundation Trust, London, UK
| | - Tihana Bicanic
- Infection Care Group, St George's University Hospitals NHS Foundation Trust, London, UK.,Institute for Infection and Immunity, St George's University of London, Cranmer Terrace, London, UK
| |
Collapse
|
4
|
Lasagna A, Muzzana M, Pedrazzoli P. Lights and shadows on the role of rhG-CSF in cancer patients during the COVID-19 pandemic and future perspectives of research. Immunotherapy 2021; 13:1369-1372. [PMID: 34585970 PMCID: PMC8544616 DOI: 10.2217/imt-2021-0219] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/03/2023] Open
Affiliation(s)
- Angioletta Lasagna
- Medical Oncology Unit, Fondazione IRCCS Policlinico San Matteo, Pavia, 27100, Italy
| | - Marta Muzzana
- Medical Oncology Unit, Fondazione IRCCS Policlinico San Matteo, Pavia, 27100, Italy.,Department of Internal Medicine and Medical Therapy, University of Pavia, Pavia, 27100, Italy
| | - Paolo Pedrazzoli
- Medical Oncology Unit, Fondazione IRCCS Policlinico San Matteo, Pavia, 27100, Italy.,Department of Internal Medicine and Medical Therapy, University of Pavia, Pavia, 27100, Italy
| |
Collapse
|
5
|
Alfarouk KO, AlHoufie STS, Ahmed SBM, Shabana M, Ahmed A, Alqahtani SS, Alqahtani AS, Alqahtani AM, Ramadan AM, Ahmed ME, Ali HS, Bashir A, Devesa J, Cardone RA, Ibrahim ME, Schwartz L, Reshkin SJ. Pathogenesis and Management of COVID-19. J Xenobiot 2021; 11:77-93. [PMID: 34063739 PMCID: PMC8163157 DOI: 10.3390/jox11020006] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/22/2021] [Revised: 05/11/2021] [Accepted: 05/12/2021] [Indexed: 12/13/2022] Open
Abstract
COVID-19, occurring due to SARS-COV-2 infection, is the most recent pandemic disease that has led to three million deaths at the time of writing. A great deal of effort has been directed towards altering the virus trajectory and/or managing the interactions of the virus with its subsequent targets in the human body; these interactions can lead to a chain reaction-like state manifested by a cytokine storm and progress to multiple organ failure. During cytokine storms the ratio of pro-inflammatory to anti-inflammatory mediators is generally increased, which contributes to the instigation of hyper-inflammation and confers advantages to the virus. Because cytokine expression patterns fluctuate from one person to another and even within the same person from one time to another, we suggest a road map of COVID-19 management using an individual approach instead of focusing on the blockbuster process (one treatment for most people, if not all). Here, we highlight the biology of the virus, study the interaction between the virus and humans, and present potential pharmacological and non-pharmacological modulators that might contribute to the global war against SARS-COV-2. We suggest an algorithmic roadmap to manage COVID-19.
Collapse
Affiliation(s)
- Khalid O. Alfarouk
- Hala Alfarouk Cancer Center, Department of Evolutionary Pharmacology and Tumor Metabolism, Khartoum 11123, Sudan;
- Research Center, Zamzam University College, Khartoum 11123, Sudan;
| | - Sari T. S. AlHoufie
- Medical Laboratories Technology Department, College of Applied Medical Sciences, Taibah University, Medina 42353, Saudi Arabia;
| | - Samrein B. M. Ahmed
- College of Medicine, University of Sharjah, Sharjah 27272, United Arab Emirates;
| | - Mona Shabana
- Pharmacology Department, Faculty of Medicine, Fayoum University, Fayoum 63514, Egypt;
| | - Ahmed Ahmed
- Department of Oesphogastric and General Surgery, University Hospitals of Leicester, Leicester LE5 4PW, UK;
| | - Saad S. Alqahtani
- Pharmacy Practice Research Unit, Clinical Pharmacy Department, College of Pharmacy, Jazan University, Jazan 45142, Saudi Arabia;
| | - Ali S. Alqahtani
- Department of Medical Laboratories Sciences, College of Applied Medical Sciences, Najran University, Najran 66446, Saudi Arabia;
| | - Ali M. Alqahtani
- Department of Pharmacology, College of Pharmacy, King Khalid University, Abha 61421, Saudi Arabia;
| | - AbdelRahman M. Ramadan
- Department of Preventive Dental Sciences, Ibn Sina National College, Jeddah 22421, Saudi Arabia;
| | - Mohamed E. Ahmed
- Research Center, Zamzam University College, Khartoum 11123, Sudan;
- Department of Surgery, Faculty of Medicine Al-Neelain University, Khartoum 11111, Sudan
| | - Heyam S. Ali
- Faculty of Pharmacy, University of Khartoum, P. O. Box 321, Khartoum 11111, Sudan;
| | - Adil Bashir
- Hala Alfarouk Cancer Center, Department of Evolutionary Pharmacology and Tumor Metabolism, Khartoum 11123, Sudan;
- Institute of Endemic Diseases, University of Khartoum, Khartoum 11111, Sudan;
| | - Jesus Devesa
- Scientific Direction, Foltra Medical Centre, 15886 Teo, Spain;
| | - Rosa A. Cardone
- Department of Biosciences, Biotechnologies, and Biopharmaceutics, University of Bari, 70126 Bari, Italy; (R.A.C.); (S.J.R.)
| | - Muntaser E. Ibrahim
- Institute of Endemic Diseases, University of Khartoum, Khartoum 11111, Sudan;
| | | | - Stephan J. Reshkin
- Department of Biosciences, Biotechnologies, and Biopharmaceutics, University of Bari, 70126 Bari, Italy; (R.A.C.); (S.J.R.)
| |
Collapse
|
6
|
Lasagna A, Ferraris E, Rizzo G, Tancredi RJ, Pedrazzoli P. Reply to Y. Ergun et al. JCO Oncol Pract 2021; 17:457. [PMID: 33797956 DOI: 10.1200/op.21.00154] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- Angioletta Lasagna
- Angioletta Lasagna, MD, Elisa Ferraris, MD, Gianpiero Rizzo, MD, Richard J. Tancredi, MD, and Paolo Pedrazzoli, MD, Medical Oncology Unit, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy and Department of Internal Medicine and Medical Therapy, University of Pavia, Pavia, Italy
| | - Elisa Ferraris
- Angioletta Lasagna, MD, Elisa Ferraris, MD, Gianpiero Rizzo, MD, Richard J. Tancredi, MD, and Paolo Pedrazzoli, MD, Medical Oncology Unit, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy and Department of Internal Medicine and Medical Therapy, University of Pavia, Pavia, Italy
| | - Gianpiero Rizzo
- Angioletta Lasagna, MD, Elisa Ferraris, MD, Gianpiero Rizzo, MD, Richard J. Tancredi, MD, and Paolo Pedrazzoli, MD, Medical Oncology Unit, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy and Department of Internal Medicine and Medical Therapy, University of Pavia, Pavia, Italy
| | - Richard J Tancredi
- Angioletta Lasagna, MD, Elisa Ferraris, MD, Gianpiero Rizzo, MD, Richard J. Tancredi, MD, and Paolo Pedrazzoli, MD, Medical Oncology Unit, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy and Department of Internal Medicine and Medical Therapy, University of Pavia, Pavia, Italy
| | - Paolo Pedrazzoli
- Angioletta Lasagna, MD, Elisa Ferraris, MD, Gianpiero Rizzo, MD, Richard J. Tancredi, MD, and Paolo Pedrazzoli, MD, Medical Oncology Unit, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy and Department of Internal Medicine and Medical Therapy, University of Pavia, Pavia, Italy
| |
Collapse
|